Hatchtech announce successful End-of-Phase 2 for head lice product DeOvo™

03 September 2012

You may also like

31 August 2016

OneVentures appoints Dr Graeme Wald to life sciences investment team

07 October 2021

Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease

13 August 2018

OneVentures invests in regional Queensland company developing treatments for autoimmune diseases

27 November 2012

Hatchtech publish data on Head Lice treatment safety study and mechanism of action

12 January 2021

Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA®

08 October 2012

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor